The federal debt-to-GDP ratio in Budget 2025 is projected to be higher compared with the 2024 fall economic statement, 'and ...
CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-thr ...
CorMedix again raises its full-year 2025 pro forma net revenue guidance to a range of $390 to $410 million, and fourth quarter net revenue guidance to a range of $115 to $135 million. In addition, the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback